U.S. administers 222.3 million doses of COVID-19 vaccines - CDC
- Futures dip as focus turns to retail earnings
- Bitcoin (BTC) Hits 3-Month Lows Before Bouncing as Musk Confirms Tesla Has Not Sold Any BTC
- AT&T (T) in Talks to Merge Media Assets with Discovery (DISCA) - WSJ
- Bill Gates Left Microsoft (MSFT) Board Amid Probe Into 'Intimate Relationship': WSJ
- Oil prices stable on confidence in demand recovery
FILE PHOTO: A nurse draws from a vial of Johnson & Johnson coronavirus disease (COVID-19) vaccine, in Los Angeles, California, U.S., March 25, 2021. REUTERS/Lucy Nicholson
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) - The United States had administered 222,322,230 doses of COVID-19 vaccines in the country as of Friday morning and distributed 286,095,185 doses, the U.S. Centers for Disease Control and Prevention said.
Those figures are up from the 218,947,643 vaccine doses the CDC said had been administered by April 22 out of 282,183,915 doses delivered.
The agency said 137,234,889 people had received at least one dose while 91,175,995 people had been fully vaccinated as of Friday.
The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnson & Johnson's one-shot vaccine as of 6:00 a.m. ET on Friday.
Advisers to the CDC are set to meet on Friday to consider whether it is safe to resume injections of the single-dose J&J vaccine, while senior health officials prepare for a green light.
A total of 7,786,204 vaccine doses have been administered in long-term care facilities, the agency said.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Households including most U.S. children to get monthly stimulus payment
- Erdogan calls on Pope to keep denouncing Gaza violence
- Taiwan's TSMC to work in separate teams to minimise COVID-19 risk
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!